• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173219 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

  l1 m2 Q  ~& ~0 h! Q4 x- j可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
* d) E# J8 {. U" M* _; X: f8 R
8 o6 V! a: L3 U& y7 Z: @7 q% ~# \- [
Sub-category:
  a, {' S6 }; A+ ]% }, }, xMolecular Targets
, A. u' P5 v! N; d: ^- i! y( h- a+ l( t5 I8 P9 s8 X* o
; ~! L0 m. N* o8 J4 z7 G1 Z
Category:
1 R, N7 H4 X$ E. g* G6 N& G8 p$ M# BTumor Biology 7 G% H: d3 z5 O  P- k# D

7 Y. r8 ^- C1 ]) j+ {. q& O4 T" \1 u1 U. y: a! ~
Meeting:
1 o, {; a4 X/ u9 s: U& m  g, e2011 ASCO Annual Meeting ( e* W% \. u+ P, N* K3 }, ^1 x

" [  b/ j1 _$ ?2 h1 U5 ?
. }5 C8 ^; K! t. S+ }$ U7 ISession Type and Session Title:
2 \$ r' }% g1 s/ \# O$ p" O/ q' ePoster Discussion Session, Tumor Biology 3 v) m0 d' H. a% n2 \7 @) R  |

  c+ u5 D- m) J) l6 a4 N) @7 B( I. h
) e! M7 l/ v9 y; xAbstract No:
5 X# v) |" r( y8 w' M5 ]10517 9 y9 B" f1 S* A0 ~3 w" \7 \

! c9 x3 o0 k  [% J! v# \* t9 y( K) y+ L, N# C3 p
Citation:
1 y; X0 a. W* ?  v; AJ Clin Oncol 29: 2011 (suppl; abstr 10517) # I( |! z$ J1 h! F

8 y1 R# z5 x  T& C
/ a. z8 W( k& e; rAuthor(s):
" q3 s2 w) p1 S) N) D9 S  C2 gJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 4 m- {: v0 P3 b( S  [6 r
+ ^6 Z$ ^) p4 o9 H4 }* ^

9 a: l: X( I1 W; K8 h4 c+ z* [- ^4 E# M  T
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.! |: L1 E$ ~2 A2 d% z3 _$ r

9 c0 ^$ B8 k- p; j* J8 wAbstract Disclosures5 G& |- X1 Z3 ^% J- Z  }$ z' {
/ K5 H* A5 v" |. v" V, A6 k
Abstract:
# b! W9 e9 w" f1 R( A9 m8 I: Z4 ~% Z: p! W  n; a% |

5 E! G. m3 g- e& R+ v7 zBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
0 u( ]5 i7 L/ K; N3 x; g
/ N/ R* d( R+ k* J ( t9 _% m, A' n7 C; d
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 1 X% B' R% w& Z. Y, S
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
* T6 A- \. Y3 H+ G" v1 A
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
+ N2 K( k6 w! W, p6 |# J易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
& U- }% B9 Q5 K9 AALK一个指标医院要900多 ...
1 Q1 d; S2 k7 q' A9 @/ P
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
  w% z. e0 C1 q4 x# y0 e6 J
3 a7 {; U* B% L9 ?9 _$ |3 h现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表